Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 2,060 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,060 shares of the firm’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the completion of the transaction, the general counsel now directly owns 486,027 shares in the company, valued at approximately $7,086,273.66. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46.

Liquidia Stock Up 2.1 %

Shares of LQDA opened at $13.86 on Thursday. The firm’s 50 day moving average is $14.75 and its 200-day moving average is $10.95. Liquidia Co. has a 12-month low of $5.71 and a 12-month high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The business had revenue of $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. On average, research analysts anticipate that Liquidia Co. will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Liquidia by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 2,843,922 shares of the company’s stock valued at $34,212,000 after purchasing an additional 69,524 shares in the last quarter. Wellington Management Group LLP purchased a new position in Liquidia during the fourth quarter valued at approximately $849,000. Price T Rowe Associates Inc. MD grew its position in Liquidia by 9.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock valued at $137,000 after purchasing an additional 989 shares in the last quarter. Bluefin Capital Management LLC purchased a new position in Liquidia during the fourth quarter valued at approximately $302,000. Finally, Barclays PLC grew its position in Liquidia by 1,105.2% during the fourth quarter. Barclays PLC now owns 103,021 shares of the company’s stock valued at $1,239,000 after purchasing an additional 94,473 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LQDA has been the subject of several research reports. Bank of America lifted their price target on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, December 21st. Wedbush reaffirmed an “underperform” rating and issued a $3.00 price target on shares of Liquidia in a report on Thursday, December 21st. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a research report on Wednesday, April 10th. LADENBURG THALM/SH SH lifted their price objective on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, HC Wainwright boosted their price target on shares of Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).